Newsroom

The Medicines for Europe association represent the pharmaceutical companies supplying the largest share of medicines across Europe, it holds its 5th conference on value-added medicines on November 7th, 2023, in Brussels.
Laurent Martin, Orphelia Pharma’s Chief Pharmaceutical Affairs Officer, will attend this conference with the story and market access of Kigabeq, the first pediatric formulation of vigabatrin for the treatment of a rare form of encephalopathic epilepsy: West syndrome.

Gilles ALBERICI, CEO at ORPHELIA Pharma and Hugues BIENAYME, General Manager will attend the BioEurope Fall meeting to be held November 6-8, 2023 in Munich, Germany. BioEurope convenes over 5,500 attendees, representing 60 countries and 2,220+ companies, making the event the industry’s largest gathering of biopharma professionals in Europe.

In June 2023, our corporate Foundation and its Endowment Fund supported Clubhouse Lyon, Cheer Up !, Dans les pas du hérisson, Night Light and Les enfants de la balle

First drinkable formulation of temozolomide for treatment of relapsed or refractory neuroblastom

Dr. Lucy METAYER, co-investigator and pediatric oncologist at the Gustave Roussy will present the results from the pediatric TEMOkids trial on October 14, 2023 during the oral session entitled “novel therapeutic approaches” at the 55th SIOP annual congress to be held in Ottawa, Canada.

Jeremy Bastid, Chief Development Officer at ORPHELIA Pharma will attend the SIOPEN annual general meeting.
The SIOPEN annual meeting brings together about 200 clinicians, investigators, researchers and patient advocates from 34 European countries to discuss on-going clinical trials, results, and work in progress in the field of neuroblastoma. 

In June 2023, our corporate Foundation and its Endowment Fund supported Audition Solidarité, Génération avant-garde, Fratries and Afuté

Jeremy Bastid, Chief Development Officer at ORPHELIA Pharma will attend the Advances in Neuroblastoma Research (ANR) meeting to be held May 15-18, 2023 in Amsterdam, the Netherlands.

We are pleased to announce that Jeremy Bastid, Chief Development Officer, and Hugues Bienaymé, General Manager and Chief Scientific Officer at ORPHELIA Pharma, will attend SIOP Europe 2023. We will be present at booth #10 located near the entrance doors to Auditorium 1.

In February 2023, our corporate Foundation and its Endowment Fund supported Animal’Hom

During the Board of Directors in december 2022, our corporate Foundation supported three new projects: Phoenix Attitude, Passerelle Ouest and Generation Cochlee.

The following pages will tell you all about the latest projects supported by the Foundation and provide you with updates on older ones

In October 2022, our corporate Foundation and its Endowment Fund supported Clubhouse, Douleurs sans Frontières and ACM Ballet.

Hugues Bienaymé, General Manager, and Jeremy Bastid, Chief Development Officer at OPRHELIA Pharma, will attend this event

ORPHELIA Pharma will participate to the first meeting “Organisation Inter Régionale Hémato-Onco pédiatrique Hauts-de-France and Grand-Est” to be held on Monday September 19, 2022 at the Faculty of Medicine of Lille, France.

During the Board of Directors in June 2022, our corporate Foundation supported five new projects: Génération Avant-Garde for a sport blade; Maison Bleue Alverne-Maison Villeneuve which is a shared house for 10 young people; hospital biographers of Plumes de Vie and Biographie hospitalière Grand Sud-Est and the 10th race against cancer of Cheer Up ! EM Lyon

This is already our 13th newsletter! It contains a review of the projects our Foundation supported in France and in Madagascar over the past six months.

During the Board of Directors in March 2022, our corporate Foundation supported five projects: a palliative care center, the Maison de Nicodème in Nantes, funding for an inclusive festival “En Scène” organized by the Zicomatic association in Savoie, musical outings for members of Tandem 64, a Paloise association. Our Institut Dominique & Tom Alberici Endowment Fund also stepped up its support for two structures hard hit by Cyclone Batsirai in Madagascar: Madatriso and Matokisa.

En février, nous avons adressé un questionnaire portant sur la Lettre d’Information de notre Fondation d’entreprise à un panel d’associations et de personnes destinataires de notre lettre et qui suivent nos activités. Ce questionnaire en ligne comprenait 9 questions, Nous avons reçu 97 réponses et nous vous en remercions. Le document joint détaille les résultats de ce sondage.

February 15th 2022 is the International Childhood Cancer Day. We are proud to announce that, during the annual symposium of Imagine For Margo (e-colloque FAST) held few days ago, we signed the charter aimed at accelerating the development of new drugs, facilitating the sharing of data for research and improving the long-term follow-up of patients 

During the Board of Directors in december 2021, our corporate Foundation supported two new projects: the production of a film promoting work in ESAT by the LADAPT association, and the implementation in Lyon hospitals of the project “Ça conte à l’hôpital” of the association Quelle Histoire!

This Newsletter is dedicated to the celebration of the 150th project supported by our Corporate Foundation and our Endowment Fund. We hope you enjoy reading it!

During the Board of Directors in october 2021, our Institut Dominique & Tom Alberici Endowment Fund supported two new projects: the funding to welcome new members for the Clubhouse Lyon, and the construction of a mini football stadium and rabbit breeding for Madatriso, new association of parents located in Antananarivo

Over the past six months, the Foundation and Institute have supported 9 projects that we present to you in this 11th newsletter.

During the Board of Directors in June 2021, our Corporate Foundation supported one new project: the financing of a weekend of hiking for the Clubhouse Lyon.

During the Board of Directors in March 2021, our Corporate Foundation and our Endowment Fund supported 2 new projects: the financing of various material for the Matokisa school set up in Madagascar by parents of disabled children and the financing of the photo book made by disabled children about the Berry Canal with the association PEP18.

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.

During the Board of Directors in December 2020, we supported 6 new projects: concerts at the hospital with the CIMCL, a saddle adapted for donkey rides with Handiane, computer equipment and furniture for AKA.MA, school for deaf children and the centers for disabled people Les Roseaux, Orchidées Blanches and Anyma.

This newsletter outlines the last projects we have supported during the second half of 2020

The 22nd of october 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support the Moebius Syndrome Association France, Au-delà de nos handicaps and the Saint-Vincent medicalized foster home

Jeremy Bastid, CEO of OREGA Biotech, will participate in the upcoming BIO-Europe conference to be held virtuallly on october 26-29, 2020.
BIO-Europe is Europe’s largest partnering conference serving the global biotech industry.Jeremy will actively take part in this business event, registered under the name of the holding company, initiative OCTALFA.

This event aims to bring together the oncology community and share the latest advances in pediatric oncology. Join the ORPHELIA Pharma virtual symposium to share on innovation in the use of temozolomide in children, which will take place on Friday October 16th between 9:15 AM and 9:35 AM (Ottawa time) by logging on to the SIOP website (SIOP-Congress.org).

The 10th of july 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support Plumes de vie, Quelle Histoire!, the Association Française du syndrome de Rett and the Association Française du syndrome d’Angelman.

This newsletter outlines the 12 projects we have supported during the first half of 2020

Since the beginning of the COVID-19 epidemic, our Corporate Foundation and our Endowment Fund have been attentive to the needs of the most deprived associations. Nine operations to support vulnerable people were conducted in March and April 2020.

Une courte lettre d’information en ces temps troublés pour vous indiquer que notre Fondation d’Entreprise et notre Fonds de Dotation restent mobilisés pour soutenir les projets associatifs dans le domaine du cancer et du handicap

The 19th of march 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Paris Newdance” with dance lesson for women affected by cancer, “Réseau Luciole” with a booklet about the surgical course of people with disabilities and “Sourire d’Onja” for a container that will send medical equipment from Reunion to Madagascar.

ORPHELIA Pharma raises 4 m€ to fund its commercial operations and clinical developments

Gilles Alberici, CEO and Jeremy Bastid, COO, will participate to the J.P. Morgan 38th Annual Healthcare Conference to be held 13-16 January 2020 in San Francisco, California, USA

initiative Octalfa wishes you a happy new year 2020

It has been a busy year for our Endowment Fund and Corporate Foundation!

The 22th of november 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “APPEL” and “le Gai-Rire”,

Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

The 18th of september 2019, the board of directors of our Endowment Fund Dominique & Tom Alberici decided to support “Douleurs sans Frontières” and “Anyma”, two projects in Madagascar.

The 18th of september 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Odynéo” and “Léthé Musicale”,

Baikowski® has signed a memorandum of understanding for the acquisition, subject to the satisfaction of conditions precedent, of Mathym SAS, a company located at Champagne-au-Montd’Or in France.

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

ORPHELIA Pharma announces today that it has entered into a collaboration agreement with the epilepsy specialist Desitin GmbH to distribute Kigabeq® in Germany.

ORPHELIA Pharma executes a collaboration and license agreement with Gustave Roussy cancer centre for the development of the first pediatric formulation of temozolomide

This sixth newsletter is packed full of information seeing as the semester has been extremely busy for both the Dominique & Tom Alberici Foundation and our Endowment Fund.

The 17th of may 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “le Sourire d’Onja”, “Sauvegarde 69”, and “Au-delà de nos Handicaps”,

We organised the Alberici Foundation Meetings on the 17th and 18th April to celebrate the 10th anniversary of the Alberici Foundation and our 100th project. Thank you to those who joined us on Wednesday evening. Some 280 of us attended the philanthropic evening of music and festivities, and it was great fun. Thanks also to those who support us but were unable to attend!

Alizé Pharma 3 to present data from its AZP-3404 program in syndromes of severe insulin resistance at ENDO 2019

Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome.

The 3rd phase, JHAM3, launched in 2018 with a collection of items such as adaptive equipment, games, educational toys and books, stationery, school supplies, clothing and household linen.
The 33 m3 container left France on the 28th December en route for Toamasina in Madagascar, and we distributed the equipment to ten Malagasy organisations during our mission between the 3rd and 17th March.

Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia.

The 8th of february 2019, the board of directors of the Fondation Dominique & Tom Alberici decided to support the MIETE by helping to organise its Fest’Dif festival in Villeurbanne (Rhône) on the 5th and 6th July 2019, which aims to promote difference and diversity.

Our Corporate Foundation and Endowment Fund are as busy as ever, with 4 projects supported this half-year and the effective implementation of the 3rd phase of the JHAM project (Jumelage Handicap Aide Madagascar – Madagascar Disability Support Twinning)…

The 19th of october 2018, the board of directors of the Fondation Dominique & Tom Alberici decided to support Magie à l’hôpital for acquisition of digital and tactile adapted tablets for the hospitalized children at Necker Hospital, and Les Chiens du Silence (Dogs of Silence), which educates and provides earphone dogs to deaf or hard of hearing people.

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

The JHAM 2 project aims to implement a collective educational programme in 2017 following an observation phase.
A container has been sent in june 2017